Algernon Pharmaceuticals Provides Update on Its Planned Phase II Clinical Trial

UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, provided an update to the market on its planned phase II clinical trial and its additional plans for 2020.     

The company is focused on developing repurposed therapeutic drugs. Drug repurposing (also known as re-profiling, re-tasking or therapeutic switching) is the application of approved drugs and compounds to treat a different disease than what they were originally developed for. The company’s objective is to minimize costs and drug development risk by taking advantage of drugs with regulatory approval in other jurisdictions and discovering alternative clinical uses.

Learn more about Algernon Pharmaceuticals Provides Update on Its Planned Phase II Clinical Trial.